149 related articles for article (PubMed ID: 12468405)
1. Molecular remission and non-Hodgkin's lymphoma.
Darby AJ; Johnson PW
Best Pract Res Clin Haematol; 2002 Sep; 15(3):549-62. PubMed ID: 12468405
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.
Corradini P; Ladetto M; Pileri A; Tarella C
Leukemia; 1999 Nov; 13(11):1691-5. PubMed ID: 10557040
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease in non-Hodgkin's lymphoma.
Schultze JL; Gribben JG
Biomed Pharmacother; 1996; 50(9):451-8. PubMed ID: 8991117
[TBL] [Abstract][Full Text] [Related]
4. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
Moos M; Schulz R; Martin S; Benner A; Haas R
Leukemia; 1998 Dec; 12(12):1971-6. PubMed ID: 9844927
[TBL] [Abstract][Full Text] [Related]
5. [Follicular (nodular) non Hodgkin's lymphoma of tonsil--case report].
Osuch-Wójcikiewicz E; Rzepakowska A; Bruzgielewicz A; Wieczorek J
Otolaryngol Pol; 2007; 61(2):203-6. PubMed ID: 17668812
[TBL] [Abstract][Full Text] [Related]
6. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
7. Significance of minimal residual disease in lymphoid malignancies.
Brüggemann M; Pott C; Ritgen M; Kneba M
Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
[TBL] [Abstract][Full Text] [Related]
8. Non-Hodgkin's lymphoma.
Maloney DG
Curr Opin Hematol; 1995 Jul; 2(4):255-61. PubMed ID: 9372005
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes.
Corradini P; Ladetto M; Zallio F; Astolfi M; Rizzo E; Sametti S; Cuttica A; Rosato R; Farina L; Boccadoro M; Benedetti F; Pileri A; Tarella C
J Clin Oncol; 2004 Apr; 22(8):1460-8. PubMed ID: 15084619
[TBL] [Abstract][Full Text] [Related]
10. Does MRD have a role in the management of iNHL?
Giudice ID; Starza ID; Foà R
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):320-330. PubMed ID: 34889425
[TBL] [Abstract][Full Text] [Related]
11. What is remission in follicular lymphoma and what is its relevance?
Buckstein R; Pennell N; Berinstein NL
Best Pract Res Clin Haematol; 2005 Mar; 18(1):27-56. PubMed ID: 15694183
[TBL] [Abstract][Full Text] [Related]
12. NCCN: Non-Hodgkin's lymphoma.
Zelenetz AD; Hoppe RT;
Cancer Control; 2001; 8(6 Suppl 2):102-13. PubMed ID: 11760551
[No Abstract] [Full Text] [Related]
13. [Detection of minimal residual disease in childhood hematological malignancies and its clinical significance].
Tang S; Lu S; Zhang X; Ran C; Huang D; Wei X
Zhonghua Xue Ye Xue Za Zhi; 2000 Jan; 21(1):27-9. PubMed ID: 11876957
[TBL] [Abstract][Full Text] [Related]
14. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
Chase ML; Armand P
Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
[TBL] [Abstract][Full Text] [Related]
16. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
Zhou A; Shi Y; Feng F; Lu S; He X; Han X
Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
[TBL] [Abstract][Full Text] [Related]
17. Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma.
Narkhede MS; Cheson BD
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):447-451. PubMed ID: 29773430
[TBL] [Abstract][Full Text] [Related]
18. Detection of residual disease in translocation (14;18) positive non-Hodgkin's lymphoma, using the polymerase chain reaction: a comparison with conventional staging methods.
Lambrechts AC; de Ruiter PE; Dorssers LC; van 't Veer MB
Leukemia; 1992 Jan; 6(1):29-34. PubMed ID: 1736011
[TBL] [Abstract][Full Text] [Related]
19. [Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes].
al Saati T; Galoin S; Roda D; Huynh A; Attal M; Delsol G
Bull Cancer; 1998 Oct; 85(10):847-54. PubMed ID: 9835862
[TBL] [Abstract][Full Text] [Related]
20. [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
Schüler F; Hirt C; Dölken L; Krüger W; Dölken G
Dtsch Med Wochenschr; 2005 Sep; 130(38):2130-4. PubMed ID: 16172952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
